PEGylated adenovirus for targeted gene therapy

Methods in Molecular Biology

Volumn 434, Issue , 2008, Pages 133-160

  O'Riordon, Catherine R ^a   Song, Antonius ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Adaptive immunity; Adenovirus; Antibody neutralization; FGF2; Innate immunity; PEGylation; Targeting

Indexed keywords

ADENOVIRIDAE; MIRIDAE; MUS;

EID: 84934439910     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-60327-248-3_9     Document Type: Article

References (67)

1. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. (1997) Isolation of a common receptor for Coxsackie B viruses and Adenoviruses 2 and 5. Science 275(5304):1320-3.
2. Tomko RP, Xu R, Philipson L. (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 94(7):3352-6.
3. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. (1994) Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 127(1):257-64.
4. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. (1993) Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73(2):309-19.
5. Nakamura T, Sato K, Hamada H. (2003) Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 77(4):2512-21.
6. Smith TA, Idamakanti N, Rollence ML, Marshall-Neff J, Kim J, Mulgrew K, Nemerow GR, Kaleko M, Stevenson SC. (2003) Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 14(8):777-87.
7. Smith TA, Idamakanti N, Marshall-Neff J, Rollence ML, Wright P, Kaloss M, King L, Mech C, Dinges L, Iverson WO, Sherer AD, Markovits JE, Lyons RM, Kaleko M, Stevenson SC. (2003) Receptor interactions involved in adenoviralmediated gene delivery after systemic administration in non-human primates Hum Gene Ther 14(17): 1595-604.
8. Vigne E, Dedieu JF, Brie A, Gillardeaux A, Briot D, Benihoud K, Latta-Mahieu M, Saulnier P, Perricaudet M, Yeh P. (2003) Genetic manipulations of adenovirus type 5 fiber resulting in liver tropism attenuation. Gene Ther 10(2): 153-62.
9. Bruder JT, Kovesdi I. (1997) Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol 71(1):398-404.
10. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, Kay MA. (1997) The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71(11):8798-807.
11. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophildependent hepatic injury in vivo. Hum Gene Ther 10(6):965-76.
12. Shifrin AL, Chirmule N, Gao GP, Wilson JM, Raper SE. (2005) Innate immune responses to adenoviral vector-mediated acute pancreatitis. Pancreas 30(2): 122-9.
13. Elkon KB, Liu CC, Gall JG, Trevejo J, Marino MW, Abrahamsen KA, Song X, Zhou JL, Old LJ, Crystal RG, Falck-Pedersen E. (1997) Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proc Natl Acad Sci USA 94(18):9814-9.
14. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. (2002) Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76(9):4580-90.
15. Liu Q, Muruve DA. (2003) Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther 10(11):935-40.
16. Jooss K, Ertl HC, Wilson JM. (1998) Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol. 72(4):2945-54.
17. Yang Y, Jooss KU, Su Q, Ertl HC, Wilson JM. (1996) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirusinfected hepatocytes in vivo. Gene Ther. 3(2):137-44.
18. Yang Y, Wilson JM. (1995) Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol. 155(5):2564-70.
19. Leissner P, Legrand V, Schlesinger Y, Hadji DA, van Raaij M, Cusack S, Pavirani A, Mehtali M. (2001) Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther. 8(1):49-57.
20. Alemany R, Curiel DT. (2001) CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.Gene Ther. 8(17):1347-53.
21. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, Wickham TJ. (2001) Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol. 75(23):11284-91.
22. Mizuguchi H, Koizumi N, Hosono T, Ishii-Watabe A, Uchida E, Utoguchi N, Watanabe Y, Hayakawa T. (2002) CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther. 9(12):769-76.
23. Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M, Stevenson SC. (2002) In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther. 5(6):770-9.
24. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H. (2006) Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum Gene Ther. 17(3):264-79.
25. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I. (1996) Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol. 70(10):6831-8.
26. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. (1996) Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol. 14(11):1574-8
27. Wickham TJ, Lee GM, Titus JA, Sconocchia G, Bakacs T, Kovesdi I, Segal DM. (1997) Targeted adenovirus-mediated gene delivery to T cells via CD3. J Virol. 71(10):7663-9.
28. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, Curiel DT. (1997) Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57(8):1447-51.
29. Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT. (1997) Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther. 4(12):1387-92.
30. Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piche A, Pierce GF, Alvarez RD, Siegal GP, Douglas JT, Curiel DT. (1998) Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res. 4(10):2455-61.
31. Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A, Aukerman SL, Pierce GF. (1999) Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 59(11):2608-14.
32. Blackwell JL, Miller CR, Douglas JT, Li H, Reynolds PN, Carroll WR, Peters GE, Strong TV, Curiel DT. (1999) Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 125(8):856-63.
33. Doukas J, Hoganson DK, Ong M, Ying W, Lacey DL, Baird A, Pierce GF, Sosnowski BA. (1999) Retargeted delivery of adenoviral vectors through fibroblast growth factor receptors involves unique cellular pathways. FASEB J. 13(11):1459-66.
34. Yoon SK, Mohr L, O'Riordan CR, Lachapelle A, Armentano D, Wands JR. (2000) Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate. Biochem Biophys Res Commun. 272(2):497-504.
35. Trepel M, Grifman M, Weitzman MD, Pasqualini R. (2000) Molecular adaptors for vascular-targeted adenoviral gene delivery. Hum Gene Ther. 11(14):1971-81.
36. Tillman BW, Hayes TL, DeGruijl TD, Douglas JT, Curiel DT. (2000) Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 60(19):5456-63.
37. Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM, Curiel DT. (2000) A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther. 2(6):562-78.
38. Ebbinghaus C, Al-Jaibaji A, Operschall E, Schoffel A, Peter I, Greber UF, Hemmi S. (2001) Functional and selective targeting of adenovirus to high-affinity Fc gamma receptor I-positive cells by using a bispeciflc hybrid adapter. J Virol. 75(1):480-9.
39. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J. (2001) Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther. 3(1):105-12.
40. Grill J, Van Beusechem VW, Van Der Valk P, Dirven CM, Leonhart A, Pherai DS, Haisma HJ, Pinedo HM, Curiel DT, Gerritsen WR. (2001) Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res. 7(3):641-50.
41. Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, Müller R, Kontermann RE. (2001) Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther. 3(6):882-91.
42. Israel BF, Pickles RJ, Segal DM, Gerard RD, Kenney SC. (2001) Enhancement of adenovirus vector entry into CD70-positive B-cell lines by using a bispecific CD70-adenovirus fiber antibody. J Virol. 75(11):5215-21.
43. Smith JS, Keller JR, Lohrey NC, McCauslin CS, Ortiz M, Cowan K, Spence SE. (1999) Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc Natl Acad Sci USA. 96(16):8855-60
44. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wads worth SC, O'Riordan CR. (1999) Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum Gene Ther. 10(16): 2615-26.
45. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR. (1999) Dressing up adenoviruses to modify their tropism. Hum Gene Ther. 10(16):2575-6.
46. Drapkin PT, O'Riordan CR, Yi SM, Chiorini JA, Cardella J, Zabner J, Welsh MJ. (2000) Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest. 105(5):589-96.
47. Lanciotti J, Song A, Doukas J, Sosnowski B, Pierce G, Gregory R, Wadsworth S, O'Riordan C (2003) Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther. 8(1):99-107
48. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. (2001) Polymer-coated adenovirus permits efficient retargeting and evades neutralizing antibodies. Gene Ther. 8(5):341-8
49. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, Francis GE. (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 10(8):1349-58.
50. Croyle MA, Chirmule N, Zhang Y, Wilson JM. (2001) "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 75(10):4792-801.
51. Croyle MA, Chirmule N, Zhang Y, Wilson JM. (2002) PEGylation of El-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther. 13(15):1887-900.
52. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, Pastore L. (2005) PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 12(7):579-87.
53. Richter AW, Akerblom E. (1983) Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol. 70(2):124-31.
54. Delgado C, Patel JN, Francis GE, Fisher D. (1990) Coupling of polyethylene glycol) to albumin under very mild conditions by activation with tresyl chloride: characterization of the conjugate by partitioning in aqueous two-phase systems. Biotechnol Appl Biochem. 12(2):119-28.
55. Francis GE, Fisher D, Delgado C, Malik F, Gardiner A, Neale D. (1998) PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques. Int J Hematol. 68(1):1-18.
56. Armentano D, Zabner J, Sacks C, Sookdeo CC, Smith MP, St George JA, Wadsworth SC, Smith AE, Gregory RJ. (1997) Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol. 71(3):2408-16.
57. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC (1993) Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53(4):891-8.
58. Maizel JV Jr, White DO, Scharff MD. (1968) The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology. 36(1):115-25.
59. Green, M., Pina, M., Kimes, R., Wensik, P., Machattie, L., and Thomas Jr., C. (1967) Adenovirus DNA. Molecular weight and conformation. Proc.Natl. Acad. Sci. USA 57, 1302-1309
60. van der Eb AJ, van Kesteren LW, van Bruggen EF. (1969) Structural properties of adenovirus DNA's. Biochim Biophys Acta. 182(2):530-41
61. Lappi DA, Matsunami R, Martineau D, Baird A. (1993) Reducing the heterogeneity of chemically conjugated targeted toxins: homogeneous basic FGF-saporin. Anal. Biochem. 212(2):446-51.
62. Zhang JD, Cousens LS, Barr PJ, Sprang SR. (1991) Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta. Proc Natl Acad Sci USA. 88(8):3446-50.
63. Heid CA, Stevens J, Livak KJ, Williams PM. (1996) Real time quantitative PCR. Genome Res. 6(10):986-94.
64. Yang Y, Li Q, Ertl HC, Wilson JM. (1995) Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 69(4):2004-15
65. Prage L, Pettersson U, Hoglund S, Lonberg-Holm K, Philipson L. (1970) Structural proteins of adenoviruses. IV. Sequential degradation of the adenovirus type 2 virion. Virology. 42(2):341-58
66. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ, Shabram P. (1995) Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther. 6(11):1403-16.
67. O'Riordan CR, Lachapelle AL, Vincent KA, Wadsworth SC. (2000) Scaleable chromatographic purification process for recombinant adeno-associated virus (rAAV). J Gene Med. 2(6):444-54.